---
document_datetime: 2025-02-13 15:33:33
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/tabrecta-epar-all-authorised-presentations_en.pdf
document_name: tabrecta-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 1.0109719
conversion_datetime: 2025-12-19 20:39:51.56963
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical form   | Route of administration   | Immediate packaging       | Pack size   |
|------------------|-------------------|------------|-----------------------|---------------------------|---------------------------|-------------|
| EU/1/22/1650/001 | Tabrecta          | 150 mg     | Film-coated tablet    | Oral use                  | blister (PVC/PE/PVDC/alu) | 60 tablets  |
| EU/1/22/1650/002 | Tabrecta          | 150 mg     | Film-coated tablet    | Oral use                  | blister (PVC/PE/PVDC/alu) | 120 tablets |
| EU/1/22/1650/003 | Tabrecta          | 200 mg     | Film-coated tablet    | Oral use                  | blister (PVC/PE/PVDC/alu) | 60 tablets  |
| EU/1/22/1650/004 | Tabrecta          | 200 mg     | Film-coated tablet    | Oral use                  | blister (PVC/PE/PVDC/alu) | 120 tablets |